What is Bristol Myers Squibb? He is going to Acquire Karuna, a Neuroscience Drugmaker, for $14 Billion
Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna Therapeutics, which makes drugs to treat schizophrenia and Alzheimer’s, in an all-cash deal valued at $14 billion as it looks to strengthen its pipeline of neuroscience drugs.
What is BMS?
Bristol Myers Squibb (BMS) is a global pharmaceutical company that engages in the discovery, development, and delivery of innovative medicines for various therapeutic areas. Here are some key aspects of Bristol Myers Squibb:
History and Overview:
Bristol Myers Squibb has a rich history dating back to its founding in 1858. Over the years, it has evolved into a major player in the pharmaceutical industry. The company is headquartered in New York City, and its mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Areas of Focus:
Bristol Myers Squibb focuses on several therapeutic areas, including oncology, cardiovascular, immunoscience, and fibrosis. The company is known for its contributions to cancer research and treatment, with a particular emphasis on immuno-oncology.
Notable Products:
BMS has developed and marketed several notable pharmaceutical products. Some of these include:
Opdivo (nivolumab), Eliquis (apixaban), Orencia (abatacept)
Research and Development:
Bristol Myers Squibb invests significantly in research and development to discover and advance new therapeutic options. The company collaborates with other organizations, including academic institutions and biotechnology companies, to drive innovation in drug development.
